Advanced Solid Tumor
Conditions
Brief summary
This is a first-in-human, dose escalation, repeat-dose, multi-center, open-label study evaluating safety, tolerability, PK, and preliminary antitumor activity of PEEL-224 in patients with advanced solid tumors.
Detailed description
This is a first-in-human, dose escalation, repeat-dose, multi-center, open-label study evaluating safety, tolerability, PK, and preliminary antitumor activity of a novel topoisomerase I inhibitor (PEEL-224) in patients with advanced solid tumors. Dose escalation will be guided by the modified toxicity probability interval-2 (mTPI-2) design with a target toxicity rate of 25% and an acceptable DLT interval of 20% to 30%. Cohorts of 2 or more patients will be sequentially enrolled at progressively higher dose levels of PEEL-224. For each dose level, all patients must complete Cycle 1 before the decision to dose escalate the next cohort of patients is made.
Interventions
DRUGPEEL-224
Lyophilized powder reconstituted with D5W
DRUGFOLF+B
infusional 5-FU, LV, and bevacizumab
Sponsors
Peel Therapeutics Inc
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Have a diagnosis of colorectal cancer confirmed by local pathology review (histology or cytology) - Part 2 only * ECOG of 0 or 1 * Have a diagnosis of advanced or metastatic solid tumor that has progressed after prior standard therapy, have been intolerant or ineligible for standard therapy, or have a malignancy for which there is no approved therapy considered standard of care * Have at least 1 documented measurable lesion as detected by radiological methods at study entry as per Response Evaluation Criteria in Solid Tumors v1.1 * Have adequate bone marrow reserve * Have adequate liver function * Have adequate renal function * Have completed prior anticancer therapy, including investigational agents, ≥28 days or 5 half lives, whichever is shorter, prior to study treatment * Have resolution of any clinically significant toxic effects of prior therapy
Exclusion criteria
* Have primary central nervous system tumors * Have brain or spinal metastases, except if treated by surgery, surgery plus focal radiotherapy, or radiotherapy alone, with no evidence of progression or hemorrhage ≤14 days prior to the first dose of PEEL-224. Have craniospinal radiotherapy ≤12 weeks prior to the first dose of PEEL-224 * Have significant abnormalities in the level of serum electrolytes * Have received neutrophil growth factor support ≤14 days prior to the first dose of PEEL 224 * Have an active infection ≤14 days prior to the first dose of PEEL-224 * Use of strong cytochrome P450 (CYP)1A2 and CYP3A4 inhibitors and/or inducers ≤14 days prior to the first dose of PEEL-224 or during the study * Use of systemic corticosteroids ≤14 days prior to the first dose of PEEL-224 * Are known to be HIV-positive, unless CD4 + lymphocyte count ≥ 300/μL, undetectable viral load; AND Receiving anti-retroviral therapy. * Have uncontrolled hepatitis B infection or hepatitis C infection; * Are pregnant or lactating, plan to become pregnant, or plan to donate gametes (ova or sperm) for in vitro fertilization during the study period or for 90 days after the patient's last study-related visit (for eligible patients only, if applicable). Eligible female patients unwilling to employ appropriate contraceptive measures to ensure that pregnancy does not occur during the study will be excluded; * Have evidence of another malignancy ≤2 years prior to screening (except in situ non melanoma skin cell cancers and in situ cervical carcinoma); * Are currently enrolled in another therapeutic clinical study or a non-therapeutic clinical study that will conflict with scheduled visits required by this study; * Have clinically significant, uncontrolled cardiovascular disease * Have history of cerebrovascular accident, transient ischemic attack, or thrombosis requiring treatment ≤3 months prior to the first dose of PEEL-224 * Have received or will receive a live vaccine ≤14 days prior to the first dose of PEEL 224. * Have tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection ≤14 days of the Screening Visit.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determine maximum tolerated dose | 28 days | Frequency, severity, and relatedness of dose limiting toxicities |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall safety and tolerability of PEEL-224 | through study completion, expected average of 6 months | Frequency, severity, and relatedness of AEs and SAEs |
| Antitumor activity assessment | every 8 weeks through study completion, expected average of 6 months | based on RECIST 1.1 |
| Cmax of PEEL-224 and its metabolite | Through 96 hours after dosing on Cycle 1 Day 1 and through 168 hours hours of dosing on Cycle 1 Day 15 | maximum blood concentration of PEEL-224 and its metabolite |
| Tmax of PEEL-224 and its metabolite | Through 96 hours after dosing on Cycle 1 Day 1 and through 168 hours hours of dosing on Cycle 1 Day 15 | Time to maximum blood concentration of PEEL-224 and its metabolite |
| changes in QTcF/QTcBBB | Through Cycle 1 (28 days) | ECG parameter readings |
Countries
United States
Outcome results
None listed